Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate

Rheumatology

Volumn 43, Issue 6, 2004, Pages 712-718

  Torrance, G W ^a,b,c   Tugwell, P ^d   Amorosi, S ^b   Chartash, E ^e   Sengupta, N ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b i3 Global   (Canada)

^c Health Utilities Incorporated   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e ABBOTT LABORATORIES   (United States)

Author keywords

Adalimumab; Health utilities index; Health utility; Health related quality of life; Outcomes; Quality adjusted life years; Rheumatoid arthritis; TNF antagonists

Indexed keywords

ADALIMUMAB; METHOTREXATE; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STATISTICAL ANALYSIS; UNITED STATES;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3042688450     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh153     Document Type: Article

References (19)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
2. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-9.
3. Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev Pharmacoeconomics Outcomes Res 2002;2:99-108.
4. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
5. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
6. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
7. Salfeld J, Kaymakçalan Z, Tracey D, Roberts A, Kamen R. Generation of fully human anti-TNF antibody D2E7 [abstract]. Arthritis Rheum 1998;41(Suppl):S57.
8. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
9. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes with adalimumab (a human anti-TNF monoclonal antibody) in the treatment of patients with active rheumatoid arthritis on concomitant methotrexate therapy: a randomized, controlled, 52-week trial. Arthritis Rheum 2004; in press.
10. Tugwell P, Revicki D, Kimel M, Boggs RL, Chartash EK. Relationship between ACR response and HRQL in adalimumab clinical trials [abstract AB0638]. Ann Rheum Dis 2003;62 (Suppl 1): 536.
11. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001;33:375-84.
13. Feeny D, Furlong W, Torrance GW et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002;40:113-28.
14. Swain L, Catlin G, Beaudet MP. The National Population Health Survey - its longitudinal nature. Health Rep 1999;10:69-82.
15. Grootendorst P, Feeny D, Furlong W. Health Utilities Index Mark 3: evidence of construct validity for stroke and arthritis in a population health survey. Med Care 2000;38:290-9.
16. Drummond M. Introducing economic and quality of life measurements into clinical studies. Ann Med 2001;33:344-9.
17. Raynauld JP, Torrance GW, Band PA et al. A prospective, randomized, pragmatic health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2): clinical results. Osteoarthritis Cartilage 2002;10:506-17.
18. Torrance GW, Raynauld JP, Walker V et al. A prospective, randomized, pragmatic health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 2 of 2): economic results. Osteoarthritis Cartilage 2002;10:518-27.
19. Torrance G, Walker V, Grossman R et al. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 1999;16:499-520.